Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00156052
Status:
COMPLETED
Last Update Posted:
2015-06-08
First Post:
2005-09-08
Brief Title:
Hypofractionated Radiotherapy Post-Lumpectomy in Women With Node Negative Breast Cancer
Sponsor:
Ontario Clinical Oncology Group OCOG
Organization:
Ontario Clinical Oncology Group OCOG
Study Overview
Official Title:
A Randomized Trial of Hypofractionated Radiotherapy Post-Lumpectomy in Women With Node Negative Breast Cancer
Status:
COMPLETED
Status Verified Date:
2015-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine if hypofractionated radiotherapy to the whole breast 4250 cGy16 fractions over 22 days is equally effective to standard fractionated radiotherapy 5000 cGy25 fractions over 35 days in women with node negative breast cancer who have undergone lumpectomy
The primary outcome is local breast recurrence and secondary outcomes include morbidity and cost effectiveness
The primary outcome is local breast recurrence and secondary outcomes include morbidity and cost effectiveness
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None